The Friday Report Blog: January 5th, 2024

Amazon’s AWS New Features Unveiled

Amazon is set to enhance its Amazon Web Services (AWS) Supply Chain with four exciting new features in 2024, aimed at improving upstream supply chain processes. This expansion will bolster the application’s existing strengths in data analysis, demand planning, and machine learning insights.

The new capabilities will support key areas like supplier orders, material and inventory forecasts, and supplier communications. This is especially beneficial for manufacturers and customers dealing with raw materials subject to fluctuating prices and availability. For instance, AWS Supply Chain Supply Planning will use data-driven approaches to optimize inventory management, helping businesses respond swiftly to demand changes and supply disruptions.

Moreover, AWS Supply Chain N-Tier Visibility will facilitate better communication and collaboration with suppliers, enabling more accurate responses to supply plans and demand changes. This feature will allow customers to share purchase orders and demand forecasts, track statuses, and identify potential sourcing risks or shortages.

AWS Supply Chain Sustainability will serve as a central hub for collecting and auditing sustainability data, streamlining the process of managing environmental compliance. Amazon Q, an AI-powered assistant, will provide summarized views of key risks, helping in the analysis of demand fluctuations and supply chain disruptions.

These new features are designed to consolidate previously isolated data, making supply planning more efficient and reducing the time spent on reconciling forecasts and collaborating with suppliers. AWS Supply Chain is already being used by notable organizations like Boston Consulting Group, Equipment Depot, and Woodside to transform their planning processes and improve supply chain efficiency.

Launched in November 2022, AWS Supply Chain aims to boost data visibility and centralization, a trend mirrored by other tech giants like Microsoft in their cloud applications and supply chain management solutions. This development reflects a growing industry focus on leveraging advanced technologies like AI and machine learning to enhance supply chain decision-making.

To read more, please click here

Solar Innovation Soars with Qcells and Microsoft’s Expanded Alliance

Qcells, a prominent solar panel manufacturer, and tech giant Microsoft are enhancing their solar energy partnership. Qcells, based in South Korea, will provide Microsoft with an impressive 12 gigawatts of solar modules and related services over eight years. This collaboration, which builds on a previous agreement for 2.5GW of solar panels, will be supported by Qcells’ new factory in Cartersville, Georgia. Once operational, this facility is set to produce an array of solar products, contributing significantly to sustainable energy production.

This expanded agreement underscores both companies’ commitment to diversifying the solar module supply chain and boosting sustainable manufacturing in the energy sector. The partnership aligns with Microsoft’s ambitious goals to go carbon-negative by 2030 and fully cover its electricity consumption with renewable energy by 2025. Qcells, a subsidiary of Hanwha, is also making substantial investments in expanding its solar manufacturing capabilities in the U.S., further advancing the country’s renewable energy infrastructure.

To read more, please click here

Revolutionizing Drug Supply Chains: U.S. Strategies for Addressing Persistent Shortages

The Biden administration is proactively addressing the persistent issue of drug shortages in the U.S. by allocating $35 million to boost domestic production of sterile injectable medicines. This significant investment, part of wider actions to strengthen national supply chains, includes expanding the Defense Production Act to encourage domestic manufacturing of essential medicines.

The initiative arrives amid rising shortages across various drug categories, including vital medications for chemotherapy, hormonal treatments, and commonly used oral liquids. With a notable increase in drug shortages recently, the focus is on enhancing the diversity and reliability of drug suppliers and manufacturers.

Concerns about the geographic concentration of raw drug ingredients in countries like China and India have been noted, particularly regarding transparency and quality control. Approximately 90-95% of critical generic sterile injectable drugs in the U.S. depend on materials from these countries, highlighting the need for diversification and strengthening domestic production.

Experts suggest that expanding domestic production is a crucial step but not the sole solution. They emphasize the need for greater transparency in the drug supply chain, from manufacturing to distribution. The dominance of major pharmacy benefit managers in the market is also a point of discussion, highlighting the necessity for policy changes in drug pricing and payment.

The Biden administration’s move, while a positive beginning, is part of a broader strategy required to revamp how prescription drugs are paid for and to ensure more equitable and sustainable pricing models that benefit both manufacturers and consumers.

To read more, please click here